Nomura H, Aoki D, Susumu N, et al. - Among individuals recruited in a randomized phase III trial examining the efficiency of adjuvant chemotherapy for endometrial cancer at a high risk of progression, the recurrent individuals were examined in order to analyze patterns and risk factors of relapse following postoperative adjuvant chemotherapy for endometrial cancer. Among 193 cases investigated, local and distant relapse were noted in 50% and 63% of patients, respectively. Along with the abdominal cavity and regional lymph nodes being the prevalent relapse sites, relapse of endometrial cancer after adjuvant chemotherapy frequently happened by 1 year following treatment. Moreover, RS was associated with disease-free interval and para-aortic lymphadenectomy among treatment-related factors.